Multidisciplinary Cancer Investigation
Tue, Nov 19, 2024
[Archive]
Volume 5, Issue 1 (Multidisciplinary Cancer Investigation - January 2021)
Multidiscip Cancer Investig 2021, 5(1): 1-8 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Esmaeilzadeh A, Khosh E. Personalized Immunology in Cancer: Paving the Way Towards a Better Quality of Life. Multidiscip Cancer Investig 2021; 5 (1) :1-8
URL: http://mcijournal.com/article-1-287-en.html
URL: http://mcijournal.com/article-1-287-en.html
1- Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Science, Zanjan, Iran , a46reza@zums.ac.ir
2- School of Medicine, Zanjan University of Medical Science, Zanjan, Iran
2- School of Medicine, Zanjan University of Medical Science, Zanjan, Iran
Abstract: (2480 Views)
Conventionally, in specific diseases, patients receive similar therapies; relying on a "one size fits all" approach. The discovery of P5 (Predictive, Preventive, Personalized, Participatory, and psycho-cognitive) improves personalized diagnosis, treatment, and prognosis. Considering the high prevalence, mortality rate, and complexity of cancers, there is a critical necessity to choose specific and individualized therapies in each case. In this point of view, immunology has a vital role in the biological variability of the patient-to-patient system and tumor microenvironment heterogeneity. Thus, it is required to improve personalized immunology in various diseases and cancers as well. Notably, personalized immunology will develop personalized cancer treatments and improve clinical outcomes. In this study, we proposed to review the essential roles of personalized immunology in cancer personalized therapies. Also, we can suggest the transformation of P5 medicine into P6 medicine, with the sixth P standing for personalized immunology.
Keywords: Precision Medicine, Immunotherapy, Immunotherapy, Adoptive Patient-Specific Modeling, Cancer Vaccines
Select article type: Review Article |
Subject:
Computational and Systems Oncology
Received: 2020/07/12 | Accepted: 2020/10/31 | ePublished: 2020/12/1
Received: 2020/07/12 | Accepted: 2020/10/31 | ePublished: 2020/12/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
